Biosensor Detects RAF Kinase Dimerization via BRET
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanisms governing RAF activation remain poorly understood, limiting the development of effective therapeutic interventions for diseases such as cancer, particularly in relation to the regulation of RAF/RAF and RAF/KSR dimer formation.
Innovation Solution
The development of an aqueous solution comprising RAF/RAF homodimers and RAF/KSR heterodimers, along with mutated RAF and KSR polypeptides, which include specific residues in the dimerization interface, to study and inhibit dimer formation, and the use of bioluminescence resonance energy transfer (BRET) assays to monitor dimerization and identify potential inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If RAF/RAF and RAF/KSR dimer formation is studied to understand activation mechanisms, then insight into RAF activation is improved, but the complexity of the system increases making therapeutic intervention difficult
Solution Approach 1:
The patent segments the RAF kinase domain into distinct functional regions, particularly focusing on the dimerization interface as a separate targetable unit. By identifying specific residues (Val563, Phe564, Leu567, Ala568) that constitute the dimerization interface, the complex dimerization process is broken down into discrete molecular interactions that can be individually targeted by inhibitors.
Solution Approach 2:
The patent introduces small molecule inhibitors as intermediaries that bind to the dimerization interface of RAF kinases. These inhibitors act as mediators that physically block the interaction between RAF monomers, preventing dimer formation without requiring modification of the RAF protein structure itself. This intermediary approach simplifies therapeutic intervention by targeting the interface rather than the entire dimerization system.
2Reliability
If specific residues in the dimerization interface are targeted to inhibit dimer formation, then therapeutic intervention effectiveness is improved, but the precision required for drug design increases
Solution Approach 1:
The patent applies local quality by focusing therapeutic intervention on specific local regions of the RAF kinase - namely the dimerization interface residues Val563, Phe564, Leu567, and Ala568. Rather than attempting to modify or target the entire kinase domain, the invention concentrates drug design efforts on this localized interface region, where small molecules can be designed to fit and block dimerization with high precision.
Solution Approach 2:
The patent employs parameter changes by modifying the binding characteristics of small molecule inhibitors to match the physical and chemical properties of the dimerization interface. By adjusting molecular parameters such as hydrophobicity, steric fit, and binding affinity of inhibitor molecules to complement the Val563, Phe564, Leu567, Ala568 interface, the precision of targeting is enhanced while maintaining therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides insights into RAF activation mechanisms and offers a potential therapeutic target for intervening in B-RAF-dependent tumorigenesis by inhibiting dimer formation, potentially leading to new cancer treatment strategies.
Implementation Method 1
the use of bioluminescence resonance energy transfer (BRET) assays to monitor dimerization and identify potential inhibitors
Data Source
AI summary
Disclosed herein are biosensors useful for detecting the dimerization of RAF and/or KSR polypeptides. These biosensors comprise fusion proteins comprising RAF and/or KSR proteins fused to bioluminescent or fluorescent proteins. Also disclosed are methods of using the biosensors to detect and measure the dimerization of RAF/RAF and RAF/KSR polypeptides by resonance energy transfer such as BRET or FRET, for example to screen for inhibitors of dimerization.